Genentech Lung-Cancer Drug Stirs Excitement On Wall Street

Genentech is waiting until May's meeting of the American Society of Clinical Oncology to present the trial's full results. Many will be listening eagerly.

"In our estimation, lung cancer is the single biggest opportunity for new cancer therapies," said Lazard analyst Joel Sendek. "The incidence of new lung cancers is over 170,000 a year

Genentech Lung-Cancer Drug Stirs Excitement On Wall Street

No comments:

Blog Archive